Take stock of the top ten hot topics in the pharmaceutical industry in 2019.

2019 is a severe test for Chinese pharmaceutical companies and practitioners.
In the 4 plus 7, medical insurance control fees, tax verification, licensing of practicing pharmacists, DRGs payment and other policies under the multiple impact of the pharmaceutical industry in the loss, reshuffle in the intensification, a number of enterprises write off, lay off, stop production, transformation and upgrading is imminent.
how do you define the pharmaceutical industry in 2019, and what are its key words? Looking back over the past year, it will finally enlighten people and bring them together in the way forward.
1, 4 plus 7 power release inventory of the 2019 pharmaceutical event, no "4 plus 7 band purchase" is incomplete.
2019, the State launched a pilot programme for the centralized procurement and use of medicines, with clear guidelines, objectives and operating methods.
september, the pilot scope of the 4-plus-7 band procurement was expanded.
then a number of provinces issued relevant supporting documents, Shandong, Jiangsu, Jiangxi, Anhui, Liaoning and other places even put 4 plus 7 products and supplies into the volume of procurement, the local version of the price war staged.
the power of 4 plus 7 band purchases is directly presented in the "soul cut price".
is not only an important measure for the country to lower drug prices and promote people's livelihood, but also a powerful pusher for pharmaceutical companies to be forced to turn to high-quality development.
addition, Sanming Alliance, Shenzhen GPO, Guangzhou GPO, Shanghai GPO, Guangxi GPO and other multi-procurement model under the joint role of drug price reduction is still the general direction.
2, pharmaceutical companies to lay off workers this year, a number of pharmaceutical companies to dissolve the sales team, and "4 plus 7" is not untested.
, the selected varieties no longer need public relations to enter the national market, the original sales staff either transformation, or to other product lines, or be laid off.
And the failed varieties, the original market share will be squeezed by the winning varieties, revenue or will decline, the cost of supporting marketing will be reduced, in this case, the sales team will also face dissolution, on the other hand, with volume procurement to give through a consistent evaluation of generic drugs and the original drug fair competition opportunities, the advantages of foreign enterprises decreased, some business withdrawal or adjustment to cope with new changes in the market.
, financial verification storm 2019, Kangmei Pharmaceuticals was exposed to financial fraud, causing market consternation, but also attracted high attention from regulators.
June, the Ministry of Finance issued a notice to verify the financial problems of 77 pharmaceutical enterprises, cost and so on became the focus of inspection, extending the inspection of related party enterprises and related sales, agents, advertising, advisory bodies, if necessary, can be extended to medical institutions.
addition, listed pharmaceutical companies have received regulatory inquiries and regulatory letters for sales expenses to grow too fast, even faster than revenue growth, and have asked for explanation of the reasonableness of sales expenses growth.
, the pharmaceutical industry shivers, how to meet the sales, has become a serious problem facing the pharmaceutical industry.
industry believes that through the verification storm, to a certain extent to deter those through financial fraud, relying on the form of high rebates to develop pharmaceutical companies, to combat corruption in the pharmaceutical sector, is conducive to the pharmaceutical industry to high-quality development.
4, "block" the focus of pharmaceutical e-commerce in 2019, perhaps not double eleven or double twelve.
this year, a number of pharmaceutical companies issued documents, "blocking" pharmaceutical e-commerce, requiring downstream distributors to stop supplying network platforms, the reason is "e-commerce prices."
the industry, pharmaceutical e-commerce innate price transparency, low-cost diversion, impact on the original price system of pharmaceutical companies, and even sales system.
the emergence of pharmaceutical e-commerce, to the sale of medicine opened up a new path to the common people to buy drugs to bring convenience, the next, pharmaceutical companies, distributors and pharmaceutical e-commerce between the game will not stop, but there is room for cooperation.
5, "Internet Plus" continued to affect 2019, the state explicitly included Internet health care in the scope of health care payments.
"Internet Plus" medical services to accelerate the development of many prescription flow platform.
And in the field of drug circulation, as a national pharmaceutical industry third-party service platform, Shenzhen Henghe Internet and China Mobile CA Center jointly developed the "001 first battalion electronic data exchange platform", "001 first battalion electronic data exchange third terminal version" small program and "electronic inspection report send and receive platform" is helping the pharmaceutical industry innovation and upgrading.
, monosynth pharmacies, clinics, health rooms can be "001 first camp electronic data exchange third terminal version" small program free of charge to send and receive first camp electronic information.
6, a strict inspection of the license of practicing pharmacists 2019 may be a watershed for practising pharmacists.
3.15 exposure of practicing pharmacists hanging up their licenses, the State Drug Administration launched a special operation to strictly investigate the retail enterprises practicing pharmacists to register their licenses.
, a group of licensee pharmacists were cleaned up and pharmacies punished.
at a time when everyone thought practicing pharmacists would be more value for money, the policy announced that practicing pharmacists could practice more.
Coupled with the unified registration of pharmaceutical chains as practising pharmacists, the head of the chain store chain can no longer be a practicing pharmacist, so that the shortage of practicing pharmacists has been alleviated, but its status is a bit awkward.
7. The new law in the field of medicine on December 1st ushered in a major event in China's pharmaceutical industry, namely, the "Vaccine Management Law" and the newly revised Drug Administration Law, which will further ensure the quality of drugs, ensure the safety and legitimate rights and interests of the public, and protect and promote public health.
8, GMP, GSP certification cancellation of the newly revised Drug Administration Law clearly, no longer accept GMP, GSP certification applications, no longer issued drug GMP, GSP certificate.
, the provincial drug regulatory bureaus followed suit.
industry insiders say that de-certification does not mean deregulation, but more stringent.
The original GMP, GSP provisions of the content still need to do, and, the previous five years a big test, now replaced with a timely examination, which means that pharmaceutical companies to always legally and compliant production, operation, temporary holding Buddha feet things, one can not do.
9, the listing license holder system With the implementation of the newly revised Drug Administration Law, the drug listing license holder system to the whole country.
there is no doubt that the country's initiative is to optimize resources, sword finger innovation.
and production licenses are conducive to drug research and development and innovation, to enhance regulatory efficiency, and to clarify the legal responsibilities of all subjects.
10, retail pharmacies access collection "4 plus 7" after the hospital drugs appear depression, pharmacies want to retain customers, drug prices may also have to be lowered.
, however, because of the different channels of purchase, pharmacy drug prices are difficult to be equal to hospital drug prices.
with Shandong, Zhejiang, Shanghai, Guangdong and other provinces and cities on the collection of drugstore health insurance drugs, drugstore and hospital-side drug prices have the possibility of unification.
, however, industry insiders say it is difficult to smooth out drug price differentials inside and outside the hospital, even if unified to the procurement platform to purchase drugs, pharmacies still rely on the price difference, while public hospitals rely on medical services.
, the attitude of the state towards the pharmaceutical industry is to speed up the marketing of innovative drugs and accelerate the reduction of the price of generic drugs.
, on the one hand, to support the research and development of domestic pharmaceutical companies, on the other hand, zero tariffs on anti-cancer drugs, further reduce the price of generic drugs, while using the huge market of 4 plus 7 to drive down prices.
on the train to 2020, the transformation pain, embrace innovation will be China's pharmaceutical industry to the future, to the international stage.
.